Q4 2024 Earnings Call Transcript January 22, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.04, expectations were $1.99. Operator: Good morning and welcome to Johnson & Johnson ...

With Spravato surpassing 1 billion in annual sales ... Lastly, I'll direct your attention to the box section of the slide, where we have also provided our income before tax, net earnings, and ...

Over the past two years of leading our home-organization coverage and writing about everything from shoe racks to drawer dividers, I’ve learned there is truly a storage bin — or box ...

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD ...

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had ...

From breaking news to special features, we're on it! Join the NonStop Local Chord group and always be in the know. WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug ...

nasal spray bottle WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive ...